Skip to main content
. Author manuscript; available in PMC: 2024 May 9.
Published in final edited form as: Immunity. 2023 Feb 14;56(5):1027–1045.e8. doi: 10.1016/j.immuni.2023.01.028

Figure 2. Crybb1-Cre recombination activity peaks during the embryonic brain development.

Figure 2.

(A) Cartoon describing the experimental design and gating strategy.

(B) Representative gating strategy for microglia and BAMs in Crybb1-Cre : R26-tdTomato mice at different timepoints.

(C) Percentage of tdTomato+ microglia and BAMs from E10.5 to P7 (n=3–6 mice/timepoint, single experiment).

(D) Absolute numbers of microglia and BAMs from E10.5 to P7 (n=3–6 mice/timepoint, single experiment).

(E) Representative confocal images of microglia and BAMs expressing tdTomato in the forebrain cortex of E17.5 embryos and P7 Crybb1-Cre : R26-tdTomato mice (n=3 embryos and n=2 pups, single experiment).

(F) Representative confocal images of microglia and BAMs expressing tdTomato in the forebrain cortex of E18.5 Crybb1-tdTomato embryos (white arrowheads) (n=5 embryos, single experiment).

(G) Representative gating strategy for CD206+ and CD206− BAMs in Crybb1-Cre : R26-tdTomato mice at different timepoints.

(H) Percentage of tdTomato+ microglia, CD206+ and CD206− BAMs in Crybb1-Cre : R26-tdTomato mice at different timepoints (n=3 mice/timepoint, single experiment).

See also Figure S2